MAHWAH, N.J. / Nov 28, 2023 / Business Wire / KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced it will host an investor day at the Mahwah, NJ headquarters on Tuesday, December 5, 2023, from 10:00 a.m. to 12:00 p.m. Eastern Time. The event will include presentations by members of management and an expert immunologist. The presentations will cover KORU Medical’s key markets, growth strategy, product portfolio, and operational and financial performance.
In-person attendance for the event requires advanced registration. Please email Hannah Jeffrey at This email address is being protected from spambots. You need JavaScript enabled to view it. by December 1, 2023, to register.
For those who cannot attend in-person, a live and archived webcast of the presentations will be available on the News/Events page of the Investors section of KORU Medical System's website at www.korumedical.com.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM™ Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The FREEDOM™ Infusion System is used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
Last Trade: | US$2.97 |
Daily Change: | 0.10 3.31 |
Daily Volume: | 2,708 |
Market Cap: | US$135.970M |
November 13, 2024 August 07, 2024 July 02, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB